FDA approves under-pressure GSK’s Jemperli for endometrial cancerThe FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, Share XFDA approves under-pressure GSK’s Jemperli for endometrial cancerhttps://pharmaphorum.com/news/fda-approves-under-pressure-gsks-jemperli-for-endometrial-cancer/
Merck gets confirmatory trial win for Keytruda in endometrial cancerMerck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a Share XMerck gets confirmatory trial win for Keytruda in endometrial cancerhttps://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
